CRISPR gene-editing therapy safely and continuously lowers cholesterol and triglycerides, first-in-human trial shows

A Cleveland Clinic first-in-human objective proceedings has shown that a one-time infusion of a gene-editing therapy utilizing CRISPR-Cas9 was effectual and harmless successful reducing LDL ("bad") cholesterin and triglycerides successful radical with medication-resistant lipid disorders done 1 twelvemonth of follow-up crossed each doses.